However, further investigation is necessary to fully understand how immunotherapy impacts the PD-1/PD-L1 intracellular tumoral axis and whether the co-expression of PD-1 and PD-L1 in cancer cells contributes to drug resistance [117]. The gene discussed is PDCD1; the disease is cancer.